A Phase I Study of Immunotherapy With E6 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs E6 TCR (Primary) ; Aldesleukin
- Indications Cervical intraepithelial neoplasia
- Focus Adverse reactions
- 31 Oct 2019 Status changed from discontinued to completed.
- 20 Sep 2019 Status changed from completed to discontinued.
- 15 May 2019 Status changed from recruiting to completed.